Livers of MASLD Patients End Up Less Fatty With Novel Injectable

(MedPage Today) — WASHINGTON — A large percentage of people with metabolic dysfunction-associated steatotic liver disease (MASLD) had their liver fat content normalize with an investigational dual agonist of the GLP-1 and glucagon receptors…

Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118499

Author :

Publish date : 2025-11-13 15:53:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Livers of MASLD Patients End Up Less Fatty With Novel Injectable

U.S. Bishops Officially Ban Gender-Affirming Care at Catholic Hospitals

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Related Posts

GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity

FDA Approves At-Home Device for Treatment-Resistant Depression

FDA Calls for New Warning on Flu Shots

Exercise vs Meds for Depression; Supplement’s Suicide Risk; Grants Terminated

U.S. Overdose Deaths Fell Through Most of 2025, Federal Data Reveal

What’s in a Name? A New One Might Help PCOS Patients

GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity

FDA Approves At-Home Device for Treatment-Resistant Depression

FDA Calls for New Warning on Flu Shots

Exercise vs Meds for Depression; Supplement’s Suicide Risk; Grants Terminated

U.S. Overdose Deaths Fell Through Most of 2025, Federal Data Reveal

What’s in a Name? A New One Might Help PCOS Patients

Cardiovascular Risk Score Shows Value in Predicting Future Eye Disease

FDA Requests Removal of Suicide Warning on GLP-1s

Categories

Archives